2016
DOI: 10.1016/j.jtho.2016.06.028
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: An extensive analysis has produced stage classification proposals for lung cancer with a robust degree of discriminatory consistency and general applicability. Nevertheless, external validation is encouraged to identify areas of strength and weakness; a sound validation should have discriminatory ability and be based on an independent data set of adequate size and sufficient follow-up with enough patients for each subgroup.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
150
0
3

Year Published

2016
2016
2023
2023

Publication Types

Select...
5
3

Relationship

2
6

Authors

Journals

citations
Cited by 201 publications
(154 citation statements)
references
References 45 publications
1
150
0
3
Order By: Relevance
“…After resection, the long-term outcomes are very good, better than that of NSCLC with separate solid tumor nodules or solid 2 nd primary NSCLCs. [15][16][17] The fairly common incidence of patients with multiple GG/L tumors and the multiplicity of such nodules stand in contrast to the infrequent incidence of patients with solid 2 nd primary lung cancers (rarely >2), suggesting these are different entities. Finally, multifocal GG/L adenocarcinomas are relatively easily recognized both clinically and by histology.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…After resection, the long-term outcomes are very good, better than that of NSCLC with separate solid tumor nodules or solid 2 nd primary NSCLCs. [15][16][17] The fairly common incidence of patients with multiple GG/L tumors and the multiplicity of such nodules stand in contrast to the infrequent incidence of patients with solid 2 nd primary lung cancers (rarely >2), suggesting these are different entities. Finally, multifocal GG/L adenocarcinomas are relatively easily recognized both clinically and by histology.…”
Section: Discussionmentioning
confidence: 99%
“…The full scope of this M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT effort is described in other papers. [15][16][17] This paper reports the work of this subcommittee for multifocal GG/L lung cancer and pneumonic-type of lung cancer.…”
Section: Introductionmentioning
confidence: 99%
“…The primary tumor is now classified into 7 categories per size ( T1a , T1b , T1c , T2a , T2b , T3 and T4 ) as compared with the 6 categories on 7 th TNM ( T1a , T1b , T2a , T2b , T3 and T4 ). The new T classification was validated on 33115 patients with NSCLC and no metastatic disease[9,11]. Robust analysis of the survival data was performed using a log-rank statistic, which confirmed prior 7 th TNM size cutoffs, and suggested further subdivision into 1-cm increments.…”
Section: Updated Tumor Descriptors (T)mentioning
confidence: 93%
“…M1b metastatic disease is associated with survival that is similar to intrathoracic metastasis ( i.e ., M1a disease). Averages survival rates are 11.4 mo for M1b and 6.3 mo for M1c disease[11,17]. …”
Section: Updated Metastasis Descriptors (M)mentioning
confidence: 99%
“…22 From this second, international database, the IASLC SPFC developed recommendations toward the eighth edition of the TNM staging system. These recommendations were published in 2015, 2016, and 2017 [23][24][25][26][27][28][29][30][31][32][33] and were once again accepted by the UICC 34 and AJCC 35 in 2017 (with AJCC implementation effective in 2018) and included in the second edition of the IASLC Staging Manual in Thoracic Oncology and the IASLC Staging Handbook in Thoracic Oncology.…”
Section: Introductionmentioning
confidence: 99%